Your browser doesn't support javascript.
loading
Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphoma.
Karmali, Reem; St-Pierre, Frederique; Ma, Shuo; Foster, Kelly D; Kaplan, Jason; Mi, Xinlei; Pro, Barbara; Winter, Jane N; Gordon, Leo I.
Affiliation
  • Karmali R; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine Northwestern University Chicago Illinois USA.
  • St-Pierre F; Division of Hematology/Oncology Northwestern University Chicago Illinois USA.
  • Ma S; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine Northwestern University Chicago Illinois USA.
  • Foster KD; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine Northwestern University Chicago Illinois USA.
  • Kaplan J; Division of Hematology/Oncology Northwestern University Chicago Illinois USA.
  • Mi X; Northwestern Medicine Lake Forest Hospital Lake Forest Illinois USA.
  • Pro B; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine Northwestern University Chicago Illinois USA.
  • Winter JN; Division of Hematology/Oncology Northwestern University Chicago Illinois USA.
  • Gordon LI; Department of Preventative Medicine - Biostatistics, Feinberg School of Medicine Northwestern University Chicago Illinois USA.
EJHaem ; 4(1): 108-114, 2023 Feb.
Article in En | MEDLINE | ID: mdl-36819145
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: EJHaem Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: EJHaem Year: 2023 Document type: Article